Results 221 to 230 of about 64,978 (265)

B-cell non-Hodgkin lymphomas

The Lancet
B-cell lymphomas occur with an incidence of 20 new cases per 100 000 people per year in high-income countries. They can affect any organ and are characterised by heterogeneous clinical presentations and courses, varying from asymptomatic, to indolent, to very aggressive cases.
Elisabeth, Silkenstedt, Gilles, Salles, Elias, Campo, Martin, Dreyling   +3 more
openaire   +2 more sources

Monoclonal gammopathies in B-cell non-Hodgkin’s lymphomas

Leukemia Research, 2003
The association of monoclonal gammopathy (MG) with B-cell non-Hodgkin's lymphomas (NHL) is a well known phenomenon. The aim of the present work was to study the incidence, type of monoclonal component and prognostic significance of MG in a population of 255 cases with B-cell NHL.
T, Economopoulos, S, Papageorgiou, V, Pappa, E, Papageorgiou, S, Valsami, D, Kalantzis, N, Xiros, J, Dervenoulas, S, Raptis   +8 more
openaire   +2 more sources

B-cell Non-Hodgkin Lymphomas with Plasmacytic Differentiation

Surgical Pathology Clinics, 2016
B-cell non-Hodgkin lymphomas with plasmacytic differentiation are a diverse group of entities with extremely variable morphologic features. Diagnostic challenges can arise in differentiating lymphoplasmacytic lymphoma from marginal zone lymphoma and other low-grade B-cell lymphomas.
Charles M, Harmon, Lauren B, Smith
openaire   +2 more sources

Use of bortezomib in B-cell non-Hodgkin’s lymphoma

Expert Review of Anticancer Therapy, 2006
The ubiquitin-proteasome pathway plays a critical role in the regulated degradation of proteins involved in cell cycle control and tumor growth. Bortezomib (Velcade, formerly known as PS-341) is a potent proteasome inhibitor. In preclinical studies, bortezomib has demonstrated activity against a variety of B-cell malignancies by inducing apoptosis and ...
Michael, Wang, Yuhong, Zhou, Liang, Zhang, C Ann, Nguyen, Jorge, Romaguera   +4 more
openaire   +2 more sources

HCV and HGV in B-cell non-Hodgkin's lymphoma

Journal of Hepatology, 1998
A causative role of hepatitis C virus infection (HCV) has been discussed in the pathogenesis of mixed cryoglobulinaemia and in B-cell non-Hodgkin's lymphoma. No data are available concerning the newly discovered hepatitis G virus (HGV) and extrahepatic manifestations such as haematological malignancies. But, HCV and HGV most probably belong to the same
V, Ellenrieder, H, Weidenbach, N, Frickhofen, D, Michel, O, Prümmer, S, Klatt, O, Bernas, T, Mertens, G, Adler, K, Beckh   +9 more
openaire   +2 more sources

B-cell non-Hodgkin's lymphoma of the paranasal sinuses

The Journal of Laryngology & Otology, 1994
AbstractPrimary nasal, paranasal, oral and pharyngeal (NPOP) lymphoma, thought to be a distinct entity among childhood lymphomas, may present with a wide variety of common ENT symptoms such as nasal obstruction, rhinorrhoea, epistaxis or sinusitis. The diagnosis may only be recognized when the disease results in symptoms such as visual loss, facial ...
S, Juman, P, Robinson, A, Balkissoon, K, Kelly   +3 more
openaire   +2 more sources

Antibody therapy of non-Hodgkin's B-cell lymphoma

Cancer Immunology, Immunotherapy, 2003
Engineering antibodies with reduced immunogenicity and enhanced effector functions, and selecting antigen targets with the appropriate specificity, density, and/or functionality, have contributed to the recent clinical successes in using unconjugated "naked" antibody therapies of B-cell lymphoma (rituximab) and breast carcinoma (Herceptin).
Paul, Chinn, Gary, Braslawsky, Christine, White, Nabil, Hanna   +3 more
openaire   +2 more sources

Therapeutic vaccines for non-Hodgkin B-cell lymphoma

Clinical and Translational Oncology, 2008
Despite current therapeutic strategies for B-cell lymphoma, including chemotherapy and transplantation, the majority of patients are not cured. The characterisation of several tumour antigens has made immunotherapy an interesting approach to the treatment of patients with lymphoma.
openaire   +2 more sources

Childhood B-Cell Non-Hodgkin's Lymphoma in Israel

Leukemia & Lymphoma, 1994
The non-Hodgkin's lymphomas of childhood and adolescence are a heterogeneous group of diseases that constitute 7-10 percent of all pediatric malignancies. Major strides have been made in recent years in understanding the pathogenesis of lymphomas at a molecular level but have not yet led to a modification of clinical management.
C, Kaplinsky, R, Zaizov
openaire   +2 more sources

Editorial Perspective—Advances in B-Cell Non-Hodgkin's Lymphoma

Leukemia & Lymphoma, 2003
Radioimmunotherapy (RIT) represents an exciting new therapeutic option for the treatment of B-cell non-Hodgkin's lymphoma (NHL), emerging at a time when significant advances have been made in NHL classification, molecular genetics and treatment.
Hagenbeek, A., Bischof Delaloye, A.
openaire   +3 more sources